Alendronate sodium
Alendronate sodium structure
|
Common Name | Alendronate sodium | ||
|---|---|---|---|---|
| CAS Number | 121268-17-5 | Molecular Weight | 325.124 | |
| Density | 1.857g/cm3 | Boiling Point | 616.7ºC at 760 mmHg | |
| Molecular Formula | C4H18NNaO10P2 | Melting Point | 245°C | |
| MSDS | Chinese USA | Flash Point | 326.7ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation.
Nat. Commun. 6 , 6218, (2015) Osteoporosis is caused by excessive activity of bone-degrading osteoclasts over bone-forming osteoblast. Standard antiosteolytic treatments inhibit bone resorption by inducing osteoclast loss, with the adverse effect of hindering also bone formation. Formatio... |
|
|
Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
Urology 81(4) , 731-7, (2013) To analyze the effects of aminobisphosphonates and thiazides on renal lithogenic activity and bone mineral density in patients with recurring renal calcium lithiasis.A prospective cohort study with 3 years of clinical follow-up data was performed. The study i... |
|
|
Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice.
Arthritis. Res. Ther. 17 , 30, (2015) Previous studies in animal models of osteoarthritis suggest that alendronate (ALN) has antiresorptive and chondroprotective effects, and can reduce osteophyte formation. However, these studies used non-physiologic injury methods, and did not investigate early... |
|
|
Enteric-coated alendronate sodium nanoliposomes: a novel formula to overcome barriers for the treatment of osteoporosis.
Expert Opin. Drug Deliv. 10(6) , 741-6, (2013) Alendronate sodium (ALS) is the most common drug used for the treatment of osteoporosis. The challenges facing ALS use include: very poor oral bioavailability (0.6%), esophageal ulcers, and complicated instructions for its use. The objective of this research ... |
|
|
Engineering of cell membranes with a bisphosphonate-containing polymer using ATRP synthesis for bone targeting.
Biomaterials 35(35) , 9447-58, (2014) The field of polymer-based membrane engineering has expanded since we first demonstrated the reaction of N-hydroxysuccinimide ester-terminated polymers with cells and tissues almost two decades ago. One remaining obstacle, especially for conjugation of polyme... |
|
|
Risk of atypical femoral fracture during and after bisphosphonate use.
Acta Orthop. 86(1) , 100-7, (2015) Use of bisphosphonates in women is associated with higher risk of atypical femoral fractures. The risk in terms of timing of use and type of bisphosphonate, and in men, remains unclear.We reviewed radiographs of 5,342 Swedish women and men aged 55 years or mo... |
|
|
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
MMW Fortschr. Med. 154 Suppl 1 , 10-21, (2012) The therapeutic strategy for the reduction of fracture risk in osteoporosis should not only aim to increase bone strength, but should also improve muscle function and reduce falls without increasing the risk of significant side effects. Since 2008 a combinati... |
|
|
[Osteoporotic fractures: not only in females].
Rev. Med. Suisse 10(424) , 767-8, (2014)
|
|
|
Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases.
Biomaterials 34(15) , 3795-806, (2013) Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases. Growing evidence suggests that low-dose taxanes and bisphosphonates possess anti-angiogenic properties. However, PTX is water-insoluble and tox... |
|
|
The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene.
Cell Cycle 14(7) , 1082-9, (2015) Pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy (GACI) are heritable ectopic mineralization disorders. Most cases of PXE and many cases of GACI harbor mutations in the ABCC6 gene. There is no effective treatment for these diso... |